...
首页> 外文期刊>The American heart journal >Defibrillation testing during implantable cardioverter-defibrillator implantation in Italian current practice: the Assessment of Long-term Induction clinical ValuE (ALIVE) project.
【24h】

Defibrillation testing during implantable cardioverter-defibrillator implantation in Italian current practice: the Assessment of Long-term Induction clinical ValuE (ALIVE) project.

机译:意大利目前的做法是在植入式心脏复律除颤器植入过程中进行除颤测试:长期诱导临床价值评估(ALIVE)项目。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Clinical practice with regard to defibrillation threshold (DFT) testing during implantable cardioverter-defibrillator (ICD) implantation varies considerably, even among experienced implanting centers. International guidelines do not as yet mandate DFT testing. OBJECTIVE: The objective of this project is to assess current clinical decision making regarding DFT testing during ICD implantation. METHODS: The ALIVE project collected data on DFT testing from a multicenter network of Italian clinicians sharing a common system for the collection, management, analysis, and reporting of clinical and diagnostic data from patients with Medtronic (Minneapolis, MN) implantable devices. RESULTS: Data on 2,082 consecutive patients implanted with a Medtronic ICD in 111 Italian centers, over the period 2007 to 2010, were analyzed. Defibrillation threshold testing was performed in 33% of cases (678/2,082). The main reasons for performing the test were physician's clinical practice ("I always perform DFT") (80%) and secondary prevention implantation (12%). The main reasons for not performing DFT testing were centers' practice (44%), primary prevention (31%), and device replacement (15%). In 22 patients, ventricular fibrillation induction was not achieved; 656 patients completed DFT testing: 633 patients (96%) performed a single test, 19 patients (3%) performed a second induction test, and 4 patients (0.6%) underwent an additional induction test. CONCLUSIONS: The preliminary results of the ALIVE project show that a great number of implant procedures are performed without DFT testing in the common practice of the participating centers. We also measured an inhomogeneous, center-dependent DFT testing behavior, which suggests the importance of defining a common guideline for ICD implant testing. Follow-up data on our patients will provide more information on the clinical value of the test.
机译:背景:即使在经验丰富的植入中心之间,植入式心脏复律除颤器(ICD)植入期间除颤阈值(DFT)测试的临床实践也存在很大差异。国际准则尚未要求DFT测试。目的:本项目的目的是评估ICD植入期间有关DFT测试的当前临床决策。方法:ALIVE项目从意大利临床医生的多中心网络收集了DFT测试数据,该网络共享一个通用系统,用于收集,管理,分析和报告来自Medtronic(明尼阿波利斯,明尼苏达州)可植入设备的患者的临床和诊断数据。结果:分析了2007年至2010年期间在111个意大利中心的2,082例连续植入Medtronic ICD的患者的数据。在33%的病例中进行了除颤阈值测试(678 / 2,082)。进行测试的主要原因是医师的临床实践(“我总是进行DFT”)(80%)和二级预防植入(12%)。不进行DFT测试的主要原因是中心的执业情况(44%),一级预防(31%)和设备更换(15%)。 22例患者未达到心室纤颤诱发; 656位患者完成了DFT测试:633位患者(96%)执行了一次测试,19位患者(3%)执行了第二次诱导测试,还有4位患者(0.6%)进行了额外的诱导测试。结论:ALIVE项目的初步结果表明,在参与中心的常规操作中,大量植入程序在没有DFT测试的情况下进行。我们还测量了不均匀,依赖于中心的DFT测试行为,这表明为ICD植入物测试定义通用准则的重要性。我们患者的随访数据将提供有关测试临床价值的更多信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号